<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02038127</url>
  </required_header>
  <id_info>
    <org_study_id>GangwonPCI</org_study_id>
    <nct_id>NCT02038127</nct_id>
  </id_info>
  <brief_title>Gangwon PCI Registry</brief_title>
  <acronym>GWPCI</acronym>
  <official_title>Prospective Registry for Patients Undergoing Coronary Angiography and Percutaneous Coronary Intervention in Gangwon Province</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yonsei University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gangwon Cardiovascular Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Yonsei University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison of&#xD;
&#xD;
        -  Biolimus-eluting stent, Biomatrix, or Biomatrix Flex stent, Biosensors, Singapore&#xD;
&#xD;
        -  Everolimus-eluting stent, Xience V, or Xience Prime, or Xience Xpedition stent, Abbott,&#xD;
           USA&#xD;
&#xD;
        -  Zotarolimus-eluting stent, Endeavor Resolute, or Endeavor Resolute Integrity stent&#xD;
           Medtronic, USA in patients with coronary artery disease treated with percutaneous&#xD;
           coronary intervention&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2013</start_date>
  <completion_date type="Anticipated">December 31, 2031</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2030</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>Device-oriented composite outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Device-oriented composite consisted of cardiac death, MI not clearly attributable to a nontarget vessel, and clinically indicated TLR at 24-month clinical follow-up</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient-oriented composite outcome</measure>
    <time_frame>24 months</time_frame>
    <description>Patient-oriented composite consisted of all-cause mortality, any MI, and any revascularization at 24-month clinical follow-up</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ARC defined stent thrombosis</measure>
    <time_frame>24 months</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">5000</enrollment>
  <condition>Coronary Artery Disease</condition>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      CBC, Electrolyte, Chemistry, Cardiac biomarker, Platelet function test&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who were at least 18 years of age, who have stable coronary artery disease (CAD)&#xD;
        or acute coronary syndrome (ACS), including myocardial infarction (MI) with or without&#xD;
        ST-segment elevation will be included in the study.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 19 years&#xD;
&#xD;
          -  Subject is able to verbally confirm understanding of risks, benefits and treatment&#xD;
             alternatives of receiving the drug-eluting stent(s) and he/she or his/her legally&#xD;
             authorized representative provides written informed consent prior to any study related&#xD;
             procedure&#xD;
&#xD;
          -  Subject must have significant stenosis (&gt;50% by visual estimate) on a native or&#xD;
             in-stent coronary artery&#xD;
&#xD;
          -  Subject must have evidence of myocardial ischemia (e.g., stable, unstable angina,&#xD;
             recent infarction, acute myocardial infarction, positive functional study or a&#xD;
             reversible changes in the ECG consistent with ischemia). In subjects with coronary&#xD;
             artery stenosis &gt;75%, evidence of myocardial ischemia does not have to be documented&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subject has a known hypersensitivity or contraindication to any of the following&#xD;
             medications: heparin, aspirin, clopidogrel, prasugrel, ticagrelor, biolimus A9,&#xD;
             everolimus, zotarolimus, stainless steel, cobalt chromium, contrast media (Patients&#xD;
             with documented sensitivity to contrast media, which can be effectively premedicated&#xD;
             with steroid and diphenhydramine may be enrolled. However, those with true anaphylaxis&#xD;
             to prior contrast media should not be enrolled.)&#xD;
&#xD;
          -  Subject in use of systemic (intravenous) biolimus A9, everolimus or zotarolimus within&#xD;
             12 months.&#xD;
&#xD;
          -  Female subject of childbearing potential, unless a recent pregnancy test is negative,&#xD;
             who possibly plans to become pregnant any time after enrollment into this study&#xD;
&#xD;
          -  Subject planned an elective surgical procedure that would necessitate interruption of&#xD;
             antiplatelet during the first 12 months post enrollment&#xD;
&#xD;
          -  Subject with non-cardiac co-morbid condition with life expectancy &lt; 2 year or that may&#xD;
             result in protocol non-compliance (per site investigator's medical judgment)&#xD;
&#xD;
          -  Subject with cardiogenic shock at presentation&#xD;
&#xD;
          -  Subject who are actively participating in another drug or device investigational&#xD;
             study, who have not completed the primary end point follow-up period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yonsei University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
    <phone>+82-33-741-0906</phone>
    <email>jyoon@yonsei.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Young Jin Youn, M.D.</last_name>
    <phone>+82-33-741-0917</phone>
    <email>younyj@yonsei.ac.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chuncheon Hallym University Hospital</name>
      <address>
        <city>Chuncheon</city>
        <state>Gangwon</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyun Hee Choi, M.D.</last_name>
      <email>jumdure@hanmail.net</email>
    </contact>
    <investigator>
      <last_name>Hyun Hee Choi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yonsei University Wonju Christian Hospital</name>
      <address>
        <city>Wonju</city>
        <state>Gangwon</state>
        <zip>220768</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
      <phone>+82-33-741-0906</phone>
      <email>jyoon@yonsei.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Young Jin Youn, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Junghan Yoon, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Seung-Hwan Lee, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sung-Gyun Ahn, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jun-Won Lee, M.D., Ph.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol Ung Choi, M.D., Ph.D.</last_name>
      <email>wmagpie@korea.com</email>
    </contact>
    <investigator>
      <last_name>Cheol Ung Choi, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 16, 2014</study_first_posted>
  <last_update_submitted>July 25, 2021</last_update_submitted>
  <last_update_submitted_qc>July 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yonsei University</investigator_affiliation>
    <investigator_full_name>Young Jin Youn, MD, PhD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

